What is CTOR's dilution risk score?

CTOR has a latest available DilutionScore record of 65/100, categorized as high dilution risk by the DilutionWatch scoring model. DilutionWatch displays SEC filing and dilution indicators for CTOR, including shelf registrations, ATM offerings, warrant exercises, PIPE deals, and reverse split signals when detected in source data.

What SEC filings does DilutionWatch track for CTOR?

DilutionWatch tracks 25 SEC filing types for CTOR including S-3 shelf registrations, 424B prospectuses (ATM offerings), S-1 registration statements, 8-K material events, warrant exercise notices, convertible note agreements, and Form 4 insider transactions. Alerts are delivered via email within minutes of a filing appearing on EDGAR.

How does stock dilution affect CTOR shareholders?

Stock dilution occurs when a company issues new shares, reducing the ownership percentage of existing shareholders. For CTOR, common dilution events include at-the-market (ATM) stock offerings, shelf registration drawdowns, warrant exercises, and convertible note conversions. Each event increases the share count and can pressure the stock price lower.

Is DilutionWatch free for CTOR tracking?

DilutionWatch provides a free tier that shows DilutionScores and basic filing history for CTOR. Premium plans ($19.95/month Basic, $39.95/month Premium) unlock real-time email alerts, the full Pulse™ feed, advanced dilution forecasts, and access to all 10,000+ tracked tickers.

CTOR Dilution Risk Score: 65/100 (HIGH)

Score Breakdown

📋 Offering Ability

80

💰 Cash Runway

0

📊 Float Risk

90

⚠️ Warrant Exposure

70

🔄 Convertible Debt

40

Dilution Forecast

🌥️

Advisory

Moderate dilution signals present

model est. 41%

🔄 Reverse Split model est. 55%

• 50-day avg $0.80 below $1 exchange minimum

📜 Warrant Exercise model 40%

• Significant warrants: 27% of shares outstanding

• Elevated warrant risk score (70/100)

📉 Score Deterioration model 10%

• Score in HIGH risk zone (65/100)

🔔 Track CTOR — Get forecast alerts →

Market Data

Market Cap$74.20M

Shares Outstanding92.98M

Float14.88M

Cash$16.56M

DebtN/A

Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

Field	Current Value	Basis
DilutionScore	65/100	DilutionWatch score record
Shares Outstanding	92.98M	Verified float table or market cache
Public Float	14.88M	Verified float table or market cache
Market Cap	$74.20M	Market data cache
Cash Runway	36.2 months	DilutionWatch score inputs
Shelf Capacity	None in current score inputs	SEC-derived dilution fields
ATM Capacity	None in current score inputs	SEC-derived dilution fields
Outstanding Warrants	25.56M	SEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 3.

Recent SEC source mix: EFFECT 2, XBRL 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

15 institutional holders · 14.78M shares

#1 ARMISTICE CAPITAL, LLC 9.19M shares

#2 BANK OF AMERICA CORP /DE/ 3.84M shares

#3 VANGUARD CAPITAL MANAGEMENT LLC 1.07M shares

+ 12 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest469.0K

Days to Cover7.3

% of Float3.1%

FINRA data as of Aug 31, 2026

Insider Buy/Sell Ratio

Recent SEC Activity

xbrl XBRL WARRANT 2026-06-30

EFFECT EFFECT 2026-03-02

EFFECT EFFECT 2026-01-12

Full SEC filing analysis available with free account →

Recent News

No recent news

Factual CTOR Dilution Snapshot

Citius Oncology, Inc. (CTOR) has a DilutionScore of 65/100, rated High dilution risk. Score date: September 12, 2026.

Stored outstanding warrants: 25.6M.
Recent SEC activity tracked for CTOR: xbrl on 2026-06-30; EFFECT on 2026-03-02; EFFECT on 2026-01-12.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.